475 related articles for article (PubMed ID: 37833948)
21. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
22. The amyloid cascade hypothesis: an updated critical review.
Kepp KP; Robakis NK; Høilund-Carlsen PF; Sensi SL; Vissel B
Brain; 2023 Oct; 146(10):3969-3990. PubMed ID: 37183523
[TBL] [Abstract][Full Text] [Related]
23. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
Tolar M; Abushakra S; Sabbagh M
Alzheimers Dement; 2020 Nov; 16(11):1553-1560. PubMed ID: 31706733
[TBL] [Abstract][Full Text] [Related]
24. Aducanumab for the treatment of Alzheimer's disease.
Tagliapietra M
Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
[TBL] [Abstract][Full Text] [Related]
25. Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
Levin J; Vöglein J; Quiroz YT; Bateman RJ; Ghisays V; Lopera F; McDade E; Reiman E; Tariot PN; Morris JC
Alzheimers Dement; 2022 Dec; 18(12):2687-2698. PubMed ID: 35212149
[TBL] [Abstract][Full Text] [Related]
26. Passive immunotherapy for Alzheimer's disease.
Guo X; Yan L; Zhang D; Zhao Y
Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
[TBL] [Abstract][Full Text] [Related]
27. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
28. Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimer's Disease.
Kabir ER; Chowdhury NM; Yasmin H; Kabir MT; Akter R; Perveen A; Ashraf GM; Akter S; Rahman MH; Sweilam SH
Curr Neuropharmacol; 2023; 21(4):787-807. PubMed ID: 36221865
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.
Loeffler DA
J Alzheimers Dis Rep; 2023; 7(1):873-899. PubMed ID: 37662616
[TBL] [Abstract][Full Text] [Related]
30. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
31. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective.
Volloch V; Rits-Volloch S
J Alzheimers Dis; 2023; 93(4):1277-1284. PubMed ID: 37212119
[TBL] [Abstract][Full Text] [Related]
32. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
[TBL] [Abstract][Full Text] [Related]
33. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
34. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
Zhang J
Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
[TBL] [Abstract][Full Text] [Related]
36. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
37. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
38. Once upon a time, the Amyloid Cascade Hypothesis.
Granzotto A; Sensi SL
Ageing Res Rev; 2024 Jan; 93():102161. PubMed ID: 38065226
[TBL] [Abstract][Full Text] [Related]
39. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
40. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems.
Li Y; Laws SM; Miles LA; Wiley JS; Huang X; Masters CL; Gu BJ
Cell Mol Life Sci; 2021 Dec; 78(23):7397-7426. PubMed ID: 34708251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
